Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra ...

Shares of Amgen (AMGN) were in the spotlight on Monday morning after the company announced that its immunotherapy Imdelltra ...

Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

Amgen (NasdaqGS:AMGN) recently announced interim results from its Phase 3 DeLLphi-304 trial for IMDELLTRA, showing ...

(RTTNews) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly extended median ...

1 The topline results from DeLLphi-304 demonstrate overwhelming clinical benefit for people living with this devastating disease and affirm IMDELLTRA as standard of care," said Jay Bradner ...

THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle ...

Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra (tarlatamab-dlle) for treating patients with small cell lung cancer (SCLC ...